Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome?

Aliment Pharmacol Ther. 2019 Apr;49(8):1086-1087. doi: 10.1111/apt.15171.

Authors

Rupert W L Leong^{1

2}, Nadeem O Kaakoush³, Yunki Y Yau^{2

4}, Valerie C Wasinger⁴

Affiliations

¹ Faculty of Medicine, South Western Clinical School, UNSW, Sydney, Australia.
² Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, Australia.
³ School of Medical Sciences, UNSW, Sydney, Australia.
⁴ Bioanalytical Mass Spectrometry Facility, UNSW, Sydney, Australia.

PMID: 30920041
DOI: 10.1111/apt.15171

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma*
Biomarkers
Colitis, Ulcerative*
Colorectal Neoplasms*
Gastrointestinal Microbiome*
Humans
Irritable Bowel Syndrome*

Substances

Biomarkers